Compare WMK & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | AGIO |
|---|---|---|
| Founded | 1912 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1994 | 2013 |
| Metric | WMK | AGIO |
|---|---|---|
| Price | $70.68 | $28.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $38.88 |
| AVG Volume (30 Days) | 112.3K | ★ 1.2M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $4,714,573,000.00 | $43,011,000.00 |
| Revenue This Year | N/A | $76.75 |
| Revenue Next Year | N/A | $170.73 |
| P/E Ratio | $62.75 | ★ N/A |
| Revenue Growth | ★ 0.01 | N/A |
| 52 Week Low | $59.99 | $22.24 |
| 52 Week High | $79.05 | $46.00 |
| Indicator | WMK | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 47.19 |
| Support Level | $67.90 | $26.61 |
| Resistance Level | $73.21 | $29.39 |
| Average True Range (ATR) | 2.04 | 1.09 |
| MACD | -0.00 | 0.23 |
| Stochastic Oscillator | 33.73 | 76.38 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.